Perkins Coie LLP
Flag tagged CD19-CAR-T cells
The present invention provides chimeric antigen receptor (CAR)-T cells modified to express a CAR fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen CD19, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the fusion protein further comprises a FLAG tag N-terminus to scFv, C-terminus to scFv, or between VH and VL. Using CD19-FLAG CAR-T cells instead of CD19 CAR-T cells, cytokine levels (Interferon-γ, IL-2 and IL6) caused by infused CAR-T cells are reduced.
Forevertek Biotechnology Co., Ltd. ProMab Biotechnologies, Inc.
C A A A C C C C C C C C C C C
C07K A61K A61P A61K C07K C07K C12N C07K C07K C07K C07K C07K C07K C07K C07K
additional additional inventional inventional additional additional inventional additional inventional additional inventional inventional additional inventional additional
Lijun Martyn Hua Vita
Wu Lewis Zhou Golubovskaya